CAR-T CD20: Phase IIa data

An open-label, Chinese Phase IIa trial in 10 patients with CD20-positive advanced B cell NHL showed that CBM-CD20.1 led to an ORR of 80%, including 5 complete remissions and 3 partial remissions, plus...